Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.00 is 100% above its 5-year average of -0.02, near the high end of its 5-year range (-0.10–0.03).
As of the fiscal period ended Tuesday, June 30, 2026. 100.00% below its 12-month average of 0.01.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00.
DEBT TO EQUITY RATIO
0.00
DEBT TO EQUITY RATIO AVG TTM
0.01
DEBT TO EQUITY RATIO AVG 3Y
0.01
DEBT TO EQUITY RATIO AVG 5Y
-0.02
DEBT TO EQUITY RATIO AVG 10Y
-0.07
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-100.00%
CURRENT VS 3Y AVG
-100.00%
CURRENT VS 5Y AVG
+100.00%
CURRENT VS 10Y AVG
+100.00%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.11
median of 774 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
vTv Therapeutics Inc.
Market Cap
$78.59M
Debt to Equity Ratio
0.00
TTM Avg
0.01
3Y Avg
0.01
5Y Avg
-0.02
Market Cap
$78.29M
Debt to Equity Ratio
0.05
TTM Avg
0.03
3Y Avg
0.03
5Y Avg
0.50
Market Cap
$78.07M
Debt to Equity Ratio
1.83
TTM Avg
0.28
3Y Avg
0.24
5Y Avg
0.19
Market Cap
$79.61M
Debt to Equity Ratio
0.02
TTM Avg
0.02
3Y Avg
0.03
5Y Avg
0.03
Market Cap
$77.54M
Debt to Equity Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$76.74M
Debt to Equity Ratio
1.08
TTM Avg
4.17
3Y Avg
2.47
5Y Avg
1.68
Market Cap
$80.80M
Debt to Equity Ratio
0.25
TTM Avg
0.08
3Y Avg
0.04
5Y Avg
0.04
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| vTv Therapeutics Inc. (VTVT) | $78.59M | 0.00 | 0.01 | 0.01 | -0.02 |
| Sera Prognostics, Inc. (SERA)vs › | $78.29M | 0.05 | 0.03 | 0.03 | 0.50 |
| Inovio Pharmaceuticals, Inc. (INO)vs › | $78.07M | 1.83 | 0.28 | 0.24 | 0.19 |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $79.61M | 0.02 | 0.02 | 0.03 | 0.03 |
| Neonc Technologies Holdings, Inc. (NTHI)vs › | $77.54M | N/A | N/A | N/A | N/A |
| Humacyte, Inc. (HUMA)vs › | $80.30M | 2.12 | 20.86 | 8.51 | 5.27 |
| Outset Medical, Inc. (OM)vs › | $76.74M | 1.08 | 4.17 | 2.47 | 1.68 |
| Citius Oncology, Inc. (CTOR)vs › | $80.80M | 0.25 | 0.08 | 0.04 | 0.04 |
| Nutriband Inc. (NTRB)vs › | $81.20M | 0.04 | 0.04 | 0.03 | 0.06 |
| MediciNova, Inc. (MNOV)vs › | $81.22M | 0.00 | 0.00 | 0.00 | 0.00 |
Debt/Equity
0.00
Current Ratio
12.48
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.00 |
| 2026-03-31 | 0.00 |
| 2025-12-31 | 0.00 |
| 2025-09-30 | 0.01 |
| 2025-06-30 | 0.03 |
| 2025-03-31 | 0.02 |
| 2024-12-31 | 0.01 |
| 2024-09-30 | 0.01 |
| 2024-06-30 | 0.02 |
| 2024-03-31 | 0.01 |
| 2023-12-31 | -0.02 |
| 2023-09-30 | -0.03 |
| 2023-06-30 | -0.02 |
| 2023-03-31 | -0.02 |
| 2022-12-31 | -0.07 |
| 2022-09-30 | -0.07 |
| 2022-06-30 | -0.07 |
| 2022-03-31 | -0.08 |
| 2021-12-31 | -0.10 |
| 2021-09-30 | -0.06 |
| 2021-06-30 | -0.02 |
| 2021-03-31 | -0.01 |
| 2020-12-31 | -0.01 |
| 2020-09-30 | -0.06 |
| 2020-06-30 | -0.08 |
| 2020-03-31 | -0.09 |
| 2019-12-31 | -0.15 |
| 2019-09-30 | -0.19 |
| 2019-06-30 | -0.22 |
| 2019-03-31 | -0.23 |
| 2018-12-31 | -0.19 |
| 2018-09-30 | -0.41 |
| 2018-06-30 | -0.27 |
| 2018-03-31 | -0.13 |
| 2017-12-31 | -0.13 |
| 2017-09-30 | -0.14 |
| 2017-06-30 | -0.18 |
| 2017-03-31 | -0.15 |
| 2016-12-31 | -0.12 |
| 2016-09-30 | 0.00 |
| 2016-06-30 | 0.00 |
| 2016-03-31 | 0.00 |
| 2015-12-31 | 0.00 |
| 2015-09-30 | 0.00 |
| 2015-06-30 | -0.69 |
| 2015-03-31 | -0.64 |
| 2014-12-31 | -0.07 |
| 2014-09-30 | 0.00 |
| 2014-06-30 | 0.00 |
| 2014-03-31 | 0.00 |
